WallStSmart

Applied DNA Sciences, Inc. (BNBX)vsBlackstone Group Inc (BX)

VS

Smart Verdict

WallStSmart Research — data-driven comparison

Blackstone Group Inc generates 687687% more annual revenue ($14.40B vs $2.09M). BX leads profitability with a 21.2% profit margin vs 0.0%. BNBX appears more attractively valued with a PEG of 1.27. BX earns a higher WallStSmart Score of 63/100 (C+).

BNBX

Hold

48

out of 100

Grade: D+

Growth: 5.3Profit: 2.5Value: 5.3Quality: 4.3
Piotroski: 3/9Altman Z: -130.37

BX

Buy

63

out of 100

Grade: C+

Growth: 6.7Profit: 9.0Value: 5.0Quality: 4.3
Piotroski: 3/9Altman Z: 1.29

Key Strengths & Concerns

Side-by-side fundamental analysis

Key Strengths

BNBX2 strengths · Avg: 10.0/10
Price/BookValuation
0.1x10/10

Reasonable price relative to book value

Revenue GrowthGrowth
34.3%10/10

Revenue surging 34.3% year-over-year

BX4 strengths · Avg: 9.5/10
Return on EquityProfitability
39.0%10/10

Every $100 of equity generates 39 in profit

Operating MarginProfitability
38.0%10/10

Strong operational efficiency at 38.0%

Market CapQuality
$150.12B9/10

Large-cap with strong market position

Profit MarginProfitability
21.2%9/10

Keeps 21 of every $100 in revenue as profit

Areas to Watch

BNBX4 concerns · Avg: 3.3/10
EPS GrowthGrowth
0.0%4/10

0.0% earnings growth

Market CapQuality
$2.72M3/10

Smaller company, higher risk/reward

Profit MarginProfitability
0.0%3/10

0.0% margin — thin

Piotroski F-ScoreQuality
3/93/10

Weak financial health signals

BX4 concerns · Avg: 3.8/10
P/E RatioValuation
31.8x4/10

Premium valuation, high expectations priced in

Price/BookValuation
12.1x4/10

Trading at 12.1x book value

EPS GrowthGrowth
3.9%4/10

3.9% earnings growth

Debt/EquityHealth
1.563/10

Elevated debt levels

Comparative Analysis Report

WallStSmart Research

Bull Case : BNBX

The strongest argument for BNBX centers on Price/Book, Revenue Growth. Revenue growth of 34.3% demonstrates continued momentum. PEG of 1.27 suggests the stock is reasonably priced for its growth.

Bull Case : BX

The strongest argument for BX centers on Return on Equity, Operating Margin, Market Cap. Profitability is solid with margins at 21.2% and operating margin at 38.0%. PEG of 1.46 suggests the stock is reasonably priced for its growth.

Bear Case : BNBX

The primary concerns for BNBX are EPS Growth, Market Cap, Profit Margin.

Bear Case : BX

The primary concerns for BX are P/E Ratio, Price/Book, EPS Growth. Debt-to-equity of 1.56 is elevated, increasing financial risk.

Key Dynamics to Monitor

BNBX profiles as a hypergrowth stock while BX is a mature play — different risk/reward profiles.

BX carries more volatility with a beta of 1.58 — expect wider price swings.

BNBX is growing revenue faster at 34.3% — sustainability is the question.

Monitor ASSET MANAGEMENT industry trends, competitive dynamics, and regulatory changes.

Bottom Line

BX scores higher overall (63/100 vs 48/100), backed by strong 21.2% margins. Both earn "Buy" and "Hold" ratings respectively — the choice depends on your investment horizon and risk tolerance.

This analysis is generated from publicly available financial data. Not financial advice.

Applied DNA Sciences, Inc.

FINANCIAL SERVICES · ASSET MANAGEMENT · USA

Applied DNA Sciences, Inc., a biotechnology company, develops and commercializes technologies to produce and detect deoxyribonucleic acid (DNA) in the Americas, Europe, Asia, and internationally. The company is headquartered in Stony Brook, New York.

Blackstone Group Inc

FINANCIAL SERVICES · ASSET MANAGEMENT · USA

Blackstone Group Inc. is an alternative asset management company specializing in real estate, private equity, hedge fund solutions, credit, secondary funds of funds, public debt and equity strategies and multiple asset classes. The company is headquartered in New York, New York with additional offices across Asia, Europe and North America.

Want to dig deeper into these stocks?